Business
Rockwell Medical Announces Upcoming Poster Presentation at the National Home Infusion Association’s 2022 Annual Conference
WIXOM, Mich., March 09, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company
About this update from Rockwell Medical, Inc.
[{"type":"text","content":"WIXOM, Mich., March 09, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced a poster presentation at the National Home Infusion Association’s (NHIA) 2022 Annual Conference, to be held March 12-16 in Nashville, Tennessee. Details of the poster presentation are as follows: Title: Management of Iron Deficiency Anemia in Home Parenteral Nutrition Patients; Challenges and Opportunities for Improvement Presenting Author:Timothy T. Chole, BSc Econ – SVP, Sales & Marketing, Rockwell Medical Co-Authors:Mark DeLegge, MD - DeLegge MedicalMarc Hoffman, MD - Chief Medical Officer, Rockwell MedicalMichelle C. Simpson, PharmD, BCSCP - Clinical Program Manager, NHIAPat Anthony, MS, RD, FASPEN - Senior Director, Organizational Growth, American Society for Parenteral and Enteral Nutrition Date and Time:Monday, March 14, 20221:30 pm – 3:00 pm ET For more details on the conference, please visit https://eventscribe.net/2022/NHIA/ A copy of the poster presentation can be accessed on the Investors section of the Company’s website at https://ir.rockwellmed.com once the presentation has concluded. About Rockwell Medical Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients’ lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. Rockwell Medical is also advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.RockwellMed.com About NHIA Founded in 1991, NHIA is the leading organization providing education, information, adv...